Navigation Links
AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
Date:8/29/2007

CASTLE ROCK, Colo., Aug. 29 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. (Nasdaq: APPY), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, reported today the company has been invited to present at the annual Roth Capital Partners New York Investor Conference to be held September 5 and 6, 2007. More than 1,200 institutional investors are expected to attend the conference, which will be held at the Westin New York at Times Square.

AspenBio's CEO Richard Donnelly is scheduled to present on Thursday, September 6, at 2:00 P.M. Eastern Time. A simultaneous Webcast will be available at: http://www.wsw.com/webcast/roth13/apnb.ob.

Mr. Donnelly will discuss progress of AspenBio key products, including a specialized assay that detects a marker in the blood associated with appendicitis. According to three studies conducted during the past 33 months, including an ongoing 400 patient study, the company's AppyScore(TM) blood test has been able to identify patients with appendicitis at a very high sensitivity level of 94% to 97%. This compares to significantly lower diagnostic success rates for expensive CT scans, which are generally considered the best diagnostic method currently available for appendicitis. With the AppyScore emergency room triage test and its sister product, AppyScreen(TM), designed for physician offices, AspenBio is targeting a significant need for more economical, accurate and faster assessment of the appendicitis condition.

Roth Capital Partners Stock Conferences are among the largest in the nation for micro and small-cap companies in the technology,
'/>"/>

SOURCE AspenBio Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)... , Fuel economy ratings for the new 2010 model...conomy.gov web site, which Oak Ridge National Lab...tment of Energy and the U.S. Environmental Protect...t fuel economy list are hybrid electrics, led by t...ist proves that hybrids have gone mainstream," sai...
(Date:11/5/2009)...ire/ -- The endangered black-footed ferrets inhabi... carnivore feeds on prairie dogs. The prairie do... population die-offs in towns occur. The U.S. Fis...erret breeding program and has been releasing trai...bitat. Unfortunately, plague can sweep through an...
(Date:11/5/2009)...tCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IA...nt and CEO of Imagenetix, will be presenting the C...ce on Thursday, December 3rd, at 10:30 AM PST at t...O ,, LD MICRO is a by-invitation only newslette...es in the micro-cap space. Since 2002, the firm ha...
(Date:11/5/2009)...ber 5, 2009 at 4:30 p.m. Eastern Time , BOTHE... - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or...audited financial results for the third quarter an...d the Company,s highlights for the third quarter o...eflect the operations of OncoGenex Technologies In...
Breaking Biology Technology:November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8
...cribe to Offering, SAN DIEGO, Dec. 21 Imagenetix... that 53 warrants totaling 3,110,710,warrant share... to the,offering. The warrants extended had exerci...er,s paid the Company $.05 per warrant share for t...pproximately $155,000.,During the offering period ...
...Neurosciences, Inc.,("Solstice") announced the app... Executive Officer. He will also continue to serve...h brings unique specialty pharmaceutical industry ...invaluable in providing guidance,leadership, and s...roaden,its product portfolio globally and map its ...
... GREENWICH, Conn., Dec. 20 /PRNewswire-,FirstCall/..., LLC, an,affiliate of GBP Capital, the majority s... today announced that the two companies have enter...enesys, lentiviral gene,delivery technology, commo... the agreement, Cell Genesys has received a paymen...
Other Biology Technology:Imagenetix Reports Results of Offer to Extend Warrants 2Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc. 2Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million 2Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million 3Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million 4Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million 5
(Date:11/4/2009)...Singapore laboratory that deciphered the DNA codes...d elephant shark, has joined The Genome 10K Projec...repository of DNA sequences on 10,000 species of a...le that currently can not be achieved. , Partici...aper published in the Nov. 5, 2009 issue of the J...
(Date:11/4/2009)...BEDFORD, Mass., Oct. 20 ...f broadband technology and biometrics software, to...ter ended September 30, 2009. ,, Michael Tzan... said, "Earlier today, we announced an agreement t...o Lantiq, a new fabless semiconductor company bein...
(Date:11/4/2009)..., CHAPEL HILL Scientists at the University of No... the University of California, San Francisco have ... predict new target diseases for existing drugs. ,...d that compares how similar the structures of all ... partners -- known as ligands -- of disease target...
Breaking Biology News(10 mins):Singapore scientists join international study of 10,000 vertebrates' genomes 2Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7Study points to new uses, unexpected side effects of already existing drugs 2CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs 52146 1CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs 52146 2CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs 52146 3Cell Discovery May Bring Science Closer to Diabetes Cure 52144 1Cell Discovery May Bring Science Closer to Diabetes Cure 52144 2Scientists locate disease switches 52141 1
...ess release is available in French . , Montreal...stant to infection with HIV, the virus that causes...ole Bernard of the Research Institute of the McGil...to a genetic explanation. Her study findings were ... simultaneous expression of certain versions of tw...
...HIA Researchers have determined a novel mechanism...o cancer, and their findings suggest that targeted...the July 15, 2008, issue of Cancer Research , res... and laboratory experiments that the anti-rejectio...pression of vascular endothelial growth factor (VE...
...NH-- Distinct genetic profiles can discern differe...utoimmune disease in which the body turns against ...t. Their discovery of distinguishing molecular sub...he complexity of a poorly understood and hard to t...is and targeted therapies. , Scleroderma is a chr...
Other Biology News:Genetic cause of innate resistance to HIV/AIDS 2Researchers discover link between organ transplantation and increased cancer risk 2Dartmouth researchers discover gene signatures for scleroderma 2Dartmouth researchers discover gene signatures for scleroderma 3
Rabbit Anti-Fruit fly (Drosophila melanogaster) SARA Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-5-Methylcytosine Monoclonal Antibody, Unconjugated, Clone 33D3 from Eurogentec
Mouse Anti-Kalinin Monoclonal Antibody, Unconjugated, Clone GB3 from Abcam
Rabbit Anti-Tryptophanyl tRNA synthetase Polyclonal Antibody, Unconjugated from Abcam
Biology Products: